Rate My Professor Matthew Piggott

Piggott’s research spans synthetic organic chemistry, medicinal chemistry, and chemical biology. His key projects include the development of MDMA-inspired compounds for Parkinson’s disease treatment, small molecule immunotherapies for cancer, reactive aldehyde trappers, medicinal chemistry targeting trypanosomiasis, total synthesis of natural products, and the design and synthesis of compounds featuring novel aromatic architectures. He has been recognized with several awards, including the CO-ADD Chemistry Prize in 2016, the Biota Award for Medicinal Chemistry in 2012 from the Royal Australian Chemical Institute, and the Athel Beckwith Lectureship in 2008. Notable publications include “A New Era for PPARγ: Covalent Ligands and Therapeutic Applications” (Journal of Medicinal Chemistry, 2025, with J.L. King et al.), “Heterocyclic core modifications in trypanosomacidal 2-[(phenylheteroaryl)ethyl] ureas” (RSC Medicinal Chemistry, 2025, with A. Toynton et al.), “An Orthogonal Conductance Pathway in Spiropyrans for Well-Defined Electrosteric Switching Single-Molecule Junctions” (Small, 2024, with D. Jago et al.), “PPARG modulators” (Patent WO 2024/211969, 2024, with J. King et al.), and “Semisynthetic Studies Establish a Role for Conjugate Halide Exchange in the Formation of Chlorinated Pyrroloiminoquinones and Related Alkaloids” (Journal of Natural Products, 2024, with S. Sala et al.). His work has garnered over 1,800 citations and contributed to collaborative drug discovery efforts.